Search Follow us

vectura

1 - 12 of 44
Sort by: popularity | newest
Page  2 3 4  of 4 | Next
Vectura

Not pausing for breath

QuickView | Pharmaceutical & healthcare | 26 Nov 2018

Building on its positive adjusted H118 EBITDA and its partnerships, Vectura has announced three recent additional developments. Partner Mundipharma received a positive EU opinion for flutiform (46% of H118 revenues) for the treatment of asthma in children, expanding its market from adults and adolescents. The agreement with Hikma to develop generic versions of GSK's Ellipta brings upfront and milestone payments and ensures Vectura's participation in the global respiratory disease market irrespective of whether generic or branded products predominate in each market. The failure of VR475 in severe uncontrolled asthma reflects more the difficulty for a non-biologic product to treat these patients.

Skyepharma

Vectura and Skyepharma announce merger

Flash note | Pharmaceutical & healthcare | 17 Mar 2016

Vectura and Skyepharma (SKP) have announced they have reached a merger agreement; under the terms of the deal SKP shareholders will be entitled to receive 2.7977 new Vectura shares for every SKP share, valuing the company at £441.3m or 410.15p per share. Our last published valuation (A shining start to 2016) of SKP is 422p/share. The rationale for the merger is to combine the complementary inhalation businesses and create an industry-leading respiratory speciality business to accelerate growth in the global inhaled market and provide shareholders of the enlarged company with a broader product and development portfolio. Based on the closing share price on 15 March, the newly enlarged group would have had a pro-forma market capitalisation of £1,014.3m.

Vectura

Daily comment

Institutional Comment | Pharmaceutical & healthcare | 30 Jun 2014

-

Greggs

Daily comment

Institutional Comment | Food & Drink | 30 Jun 2014

-

Petrofac

Daily comment

Institutional Comment | Engineering | 24 Jun 2014

-

Chemring

Daily comment

Institutional Comment | Aerospace & Defence | 24 Jun 2014

-

Vectura

Daily comment

Institutional Comment | Pharmaceutical & healthcare | 24 Jun 2014

-

Xaar

Daily comment

Institutional Comment | Electronics & Electrical Equipment | 24 Jun 2014

-

Ryanair

Daily comment

Institutional Comment | Travel & Leisure | 24 Jun 2014

-

Vectura

Getting a second wind

QuickView | Pharmaceutical & healthcare | 31 Mar 2014

Vectura's €130m acquisition of private German smart nebuliser technology company Activaero has addressed its pipeline gap in a single deal, adding seven clinical programmes based on the FAVORITE inhalation platform. These should effect a second wave of regulatory filings for branded respiratory products from 2017 onwards. As outlined at its recent investor day, Vectura now has a broader and more balanced pipeline, underpinned by formulation and device technologies, with which to build a sustainable business focused on treating airways diseases. Upcoming catalysts for H114 remain US filings of NVA237 and QVA149, and top-line VR506 data.

Vectura

Breathe a sigh of relief

QuickView | Pharmaceutical & healthcare | 20 Dec 2013

Vectura's partner Sandoz has received its first European approval in Denmark for AirFluSal, a generic version of GSK's Seretide for asthma/chronic obstructive pulmonary disease (COPD). AirFluSal, formerly VR315, is delivered via Vectura's proprietary Gyrohaler inhaler. It is the third Vectura-developed respiratory product to receive European approval following those of the two Novartis-partnered COPD drugs, Seebri Breezhaler (in 2012) and Ultibro Breezhaler (earlier in 2013). Royalties on product sales will strengthen an already solid cash balance of £65.5m.

Futura Medical

Edison healthcare quarterly: Immuno-oncology 2: The combos come

Sector Commentary: | Pharmaceutical & healthcare | 06 Nov 2013

-